Drug-Induced Liver Injury

Idiosyncratic Liver Injury Associated with Drugs (ILIAD)

Enrollment Status: OPEN

The goal of the ILIAD protocol is to create a database and bank of biological specimens (DNA, plasma, lymphocytes) from individuals with severe drug-induced liver injury (DILI) due to isoniazid (INH), phenytoin (Dilantin), amoxicillin/clavulanate (Augmentin), or valproic acid (Depakote) after January 1, 1994. This study is funded by the NIH/NIDDK.

Study Design

• Telephone or personal interview of medical history surrounding DILI event
• Single blood draw
• Participant receives $75

A Multicenter, Longitudinal Study of Drug-Induced and Complementary and Alternative Medications-Induced Liver Injury

Enrollment Status: OPEN

The goal of this NIH study is to prospectively identify bona fide cases of liver injury due to drugs and complementary and alternative medications (CAM) within 6 months of onset. Clinical data, blood, DNA, and urine will be collected from affected patients and matched controls for mechanistic and genetic studies.

Study Design

• All subjects have a baseline and 6-month follow-up visit at the General Clinical Research Center, which includes surveys, medical history, blood and urine collection.
• Patients with liver injury at 6 months return for 12- and 24-month visits.

Costs

• Costs of study lab tests provided by sponsor (NIDDK).
• Subjects receive $50 for each completed study visit.

Contact persons:

• Suzanne Welch at (734) 936-4886 or toll free 1-866-UM-LIVER or e-mail: swelc@med.umich.edu

• Robert Fontana, MD e-mail: rfontana@med.umich.edu)

For more information see the following websites
Drug-Induced Liver Injury Network at http://dilin.dcri.duke.edu/index.html

NIH funds network to study drug-induced liver injury at http://www.nih.gov/news/pr/nov2004/niddk-19.htm

Press Release: U-M helps lead national study of liver damage at http://www.med.umich.edu/opm/newspage/2004/liverstudy.htm